Table 1.

Baseline characteristics between never-users and ever-users of rosiglitazone

Variables	Never-users		Ever-users		P
	n	%	n	%
n = 886418	783321		103097
Age (years)
<40	33874	4.32	3269	3.17	<0.0001
40-49	102887	13.13	11623	11.27
50-59	199819	25.51	27204	26.39
60-69	200241	25.56	29608	28.72
≥70	246500	31.47	31393	30.45
Sex (men)	399333	50.98	49282	47.80	<0.0001
Diabetes duration (years)
<1	70381	8.98	1434	1.39	<0.0001
1-3	133250	17.01	7184	6.97
3-5	123610	15.78	11094	10.76
≥5	456080	58.22	83385	80.88
Hypertension	443728	56.65	77740	75.40	<0.0001
Chronic obstructive pulmonary disease	114018	14.56	24177	23.45	<0.0001
Cerebrovascular disease	116947	14.93	25453	24.69	<0.0001
Nephropathy	93744	11.97	23717	23.00	<0.0001
Ischemic heart disease	174225	22.24	40511	39.29	<0.0001
Peripheral arterial disease	89324	11.40	24510	23.77	<0.0001
Eye disease	63803	8.15	21179	20.54	<0.0001
Obesity	11423	1.46	1961	1.90	<0.0001
Dyslipidemia	371714	47.45	69015	66.94	<0.0001
Other cancer prior to baseline	93619	11.95	13058	12.67	<0.0001
Sulfonylurea	577003	73.66	99140	96.16	<0.0001
Metformin	512063	65.37	96850	93.94	<0.0001
Acarbose	80640	10.29	38971	37.80	<0.0001
Insulin	102359	13.07	39119	37.94	<0.0001